pharmazz

        | Novel drug product in clinical development to treat hypovolemic shock |                   | Marketing authorization received for Lyfaquin™ (centhaquine) |                                   | Phase 2 Results on Efficacy of PMZ-2010 (Centhaquin) in Patients with Hypovolemic Shock Presented at AHA Scientific Sessions 2018 |                                                 | Clinical phase II results indicate that PMZ-2010 (centhaquin) is a novel highly effective resuscitative agent for hypovolemic shock. |                        

Developing products that are first-in-class with unique mechanism of action and are different from those of existing therapies

about

Pharmazz, Inc.

Pharmazz, Inc. is a clinical stage pharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics that target critical care medicine. The company is developing several clinical-stage product candidates, PMZ-2010 (Centhaquine), PMZ-1620 (Sovateltide) and PMZ-2123 for which it holds global marketing rights.

Established in 2010, Pharmazz, Inc. is an emerging global pharmaceutical company. Focus of the company is to discover, acquire, develop and market novel pharmaceutical products for use in critical care and hospital settings.

Product Pipeline

Product
Pre-Clinical
Clinical

phase 1

phase 2

phase 3

Market

Hypovolemic Shock (Centhaquine - Lyfaquin®)

Septic Shock (Centhaquine)

Acute Kidney Injury (Centhaquine)

Cardiac Arrest (Centhaquine)

Cerebral Ischemic Stroke (Sovateltide)

Alzheimer's Disease (Sovateltide)

Acute Spinal Cord Injury (Sovateltide)

Diabetic Ketoacidosis (PMZ-2123)

Opioid Tolerance (PMZ-2123)

Products

Hypovolemic Shock

Hypovolemic Shock

Septic Shock

Septic Shock

Acute Kidney Injury

Acute Kidney Injury

Cardiac Arrest

Cardiac Arrest

Cerebral Ischemic Stroke

Cerebral Ischemic Stroke

Alzheimer's Disease

Alzheimer's Disease

Acute Spinal Cord Injury

Acute Spinal Cord Injury

Diabetic Ketoacidosis

Diabetic Ketoacidosis

Opioid Tolerance

Opioid Tolerance

phase 1